Current Report Filing (8-k)
06 Maggio 2022 - 11:19PM
Edgar (US Regulatory)
0001630113
false
0001630113
2022-05-02
2022-05-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): May 2, 2022
BIOTRICITY
INC.
(Exact
name of registrant as specified in its charter)
| Nevada |
|
001-40761 |
|
47-2548273 |
(State
or Other Jurisdiction of
Incorporation or Organization) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
275
Shoreline Drive, Suite 150
Redwood
City, California
94065
(Address
of Principal Executive Offices)
(650)
832-1626
(Registrant’s Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b):
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.001 per share |
|
BTCY |
|
NASDAQ
Capital Markets |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
May 2, Stephen Salmon a member of the Board of
Directors of Biotricity Inc. (the “Company”) and the Company’s Compensation Committee, resigned from the Company’s
Board of Directors effective May 2, 2022. Mr. Salmon did not advise the Company of any disagreement with the Company on any matter relating
to its operations, policies or practices.
On
May 4, 2022, the Board of Directors of the Company appointed Ronald McClurg to the Board of Directors to fill the vacancy created by
Mr. Salmon’s resignation. There are no arrangements or understandings between Mr. McClurg and any other persons pursuant to which
he was selected as a director, Mr. McClurg will receive compensation as a non-employee director in accordance with the company’s
non-employee director compensation practice. Mr. McClurg has no direct or indirect material interest in any transaction required to be
disclosed pursuant to Item 404(a) of Regulation S-K. Mr. McClurg has not yet been appointed to any committees of the board.
Mr.
McClurg is a senior financial executive with experience leading the finance, administrative and IT functions in private and public companies.
From 2003 to 2019 , Mr. McClurg was the Vice President, Finance & Administration and Chief Financial Officer for Incisive Surgical,
Inc. Since 2020 Mr. McClurg has been a consultant.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
Date:
May 5, 2022
| |
BIOTRICITY
INC. |
| |
|
|
| |
By: |
/s/
Waqaas Al-Siddiq |
| |
|
Waqaas
Al-Siddiq |
| |
|
Chief
Executive Officer |
Grafico Azioni Biotricity (QB) (USOTC:BTCY)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Biotricity (QB) (USOTC:BTCY)
Storico
Da Dic 2023 a Dic 2024
